Moberg Pharma (MOB) Q1 2026 earnings summary

Executive summary

• Achieved strong operational execution and international expansion, especially in APAC through an expanded license agreement with Karo Healthcare for Australia, New Zealand, South Korea, and Taiwan.

• Maintained market leadership for TerclaraⓇ in Sweden and Norway, with significant year-over-year market share gains.

• Regulatory processes for further European launches are ongoing, with launches dependent on national health authority approvals.

Financial highlights

• Net revenue for Q1 2026 was SEK 4.9 million, up from SEK 3.9 million year-over-year.

• EBITDA improved to SEK -1.5 million from SEK -3.7 million; EBIT was SEK -1.9 million versus SEK -4.1 million.

• Profit for the period was SEK -1.3 million, compared to SEK -2.8 million in Q1 2025.

• Cash and cash equivalents at period end were SEK 222.5 million, down from SEK 268.9 million a year earlier.

• Cash flow from operating activities was SEK -3.5 million, and total change in cash was SEK -8.5 million for the quarter.

Outlook and guidance

• Focus remains on commercializing MOB-015 in approved European markets and expanding into new APAC territories.

• Ongoing regulatory processes in 11 European countries; launches to follow approvals.

• Long-term U.S. market entry remains a goal, pending additional clinical data.